GlaxoSmithKline plc Surges On ViiV Spin-Off Plans And Upbeat Revenue Guidance

Now could be a great time to buy GlaxoSmithKline plc (LON: GSK). Here’s why.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) are up by as much as 2.5% today after the company released its fourth-quarter results. While they showed a fall in the company’s top line, there is at least a degree of optimism now present regarding the future prospects for the company, as it seeks to move on from what have been a challenging few years.

So, even though revenue was down by 5% in the quarter, 3% for the full year and is expected to continue to disappoint in the first half of the year as the US in particular poses a headwind, the second half of the year is forecast to mark a significant improvement. For example, GlaxoSmithKline is anticipating that it will start to regain market share for its respiratory drugs after sales of Advair continued to fall and new drugs, Breo and Anoro, were slower than expected.

Furthermore, the company has initiated a review of its ViiV Healthcare division (which focuses on HIV medicines) and is mulling over a 2016 spin-off, with a decision set to be reached in the next few months. If it goes ahead, this move could improve sentiment in GlaxoSmithKline and provide support for its share price, as ViiV has very strong growth potential.

Meanwhile, GlaxoSmithKline’s all-important cost cutting programme remains on track, with around £400m of efficiencies made during the course of 2014. And, with earnings coming in slightly above market forecasts (at 27.3p per share versus forecasts of 25.9p per share), it would not be a major surprise for investor sentiment to continue to tick upwards during the next few weeks.

Looking Ahead

Clearly, GlaxoSmithKline is going through a period of significant change and, as such, its share price could remain relatively volatile in the near term. However, it remains a company with huge potential, as evidenced by the prospect of a ViiV spin-off, as well as the potential for an asset swap with Novartis.

Furthermore, it still offers excellent value for money at its current price level. This is perhaps evidenced best by its dividend yield, which currently stands at an incredible 5.4%. This indicates that it is an excellent income play, but also that its shares are very attractively priced right now.

Certainly, top-line growth may splutter in the short run but, with an improving pipeline of new drugs and the potential for significant cost savings, its bottom line could surprise on the upside over the medium to long term. As such, it could be worth buying at the present time – especially if you are a long term investor.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »